FOXA1 and colonic neoplasm: To ensure that the antiproliferative effects of ORIC-101 were specifically mediated by GR inhibition, we tested ORIC-101 in GR-negative HT-29 colon cancer cells and FOXA1-independent A549 lung cancer cells.